Current Pharmacogenomics and Personalized Medicine This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Gender Differences in Response to Therapy for Cardiovascular Diseases
Conclusion: Up to date, data on gender differences in cardiovascular therapy are still controversial, and overall no established factors have been identified to discriminate the different approach in the choice of cardiovascular drugs by gender. Then further more structured and bigger trials should be performed to target these issues, and to better clarify the underlining involved mechanisms. (Source: Current Pharmacogenomics and Personalized Medicine)
Source: Current Pharmacogenomics and Personalized Medicine - June 23, 2017 Category: Genetics & Stem Cells Source Type: research

Management and Treatment of Cardiovascular Diseases in the Elderly
Conclusion: new studies involving frail elderly patients are needed in order to provide evidence-based treatment strategies and to allow more personalized medical approaches. (Source: Current Pharmacogenomics and Personalized Medicine)
Source: Current Pharmacogenomics and Personalized Medicine - June 23, 2017 Category: Genetics & Stem Cells Source Type: research

Editorial: “New Challenges in the Treatment of Cardiovascular Diseases: From Evidence-based Medicine to Personalized Care”
(Source: Current Pharmacogenomics and Personalized Medicine)
Source: Current Pharmacogenomics and Personalized Medicine - June 23, 2017 Category: Genetics & Stem Cells Source Type: research

Preface
(Source: Current Pharmacogenomics and Personalized Medicine)
Source: Current Pharmacogenomics and Personalized Medicine - June 23, 2017 Category: Genetics & Stem Cells Source Type: research

Meet Our Editorial Board Member
(Source: Current Pharmacogenomics and Personalized Medicine)
Source: Current Pharmacogenomics and Personalized Medicine - June 23, 2017 Category: Genetics & Stem Cells Source Type: research

Impact of New Technologies on Pharmacogenomics
Conclusion: The great development of new technologies can open promising insight on pharmacogenomics, allowing to study genes involved in pharmacokinetics and pharmacodynamics and providing holistic information of drug toxicity and efficacy. The understanding of therapeutic effects, adverse events and drugs interaction is still limited by incomplete knowledge of cellular pathways, therefore inferring interacting biological molecules involved in drug response is required. (Source: Current Pharmacogenomics and Personalized Medicine)
Source: Current Pharmacogenomics and Personalized Medicine - April 25, 2017 Category: Genetics & Stem Cells Source Type: research

Acknowledgements to reviewers
(Source: Current Pharmacogenomics and Personalized Medicine)
Source: Current Pharmacogenomics and Personalized Medicine - April 25, 2017 Category: Genetics & Stem Cells Source Type: research

Exome Sequencing of Ovarian Cancer Patients to Identify Variants Predictive of Sensitivity to Platinum-based Chemotherapy
Conclusion: pSNVs load in certain genes may be predictive of sensitivity to platinum in ovarian cancer. With validation of these findings, it is possible that a new marker predictive of patient response may be identified. (Source: Current Pharmacogenomics and Personalized Medicine)
Source: Current Pharmacogenomics and Personalized Medicine - April 25, 2017 Category: Genetics & Stem Cells Source Type: research

Newer Insights in Personalized and Evidence Based Medicine- the Role of MicroRNAs
Conclusion: A significant fraction of all mRNAs transcribed in a cell are regulated by miRNAs. miRNAs implicated in a given disease may interfere with drug action and metabolism. Further research is needed to understand the association between miRNA, mRNAs, diseases and pharmacokinetics and dynamics. (Source: Current Pharmacogenomics and Personalized Medicine)
Source: Current Pharmacogenomics and Personalized Medicine - April 25, 2017 Category: Genetics & Stem Cells Source Type: research

New Developments of Differentiation Therapy of Acute Myeloid Leukemia
Conclusion: These observations suggest new successful developments of AML differentiation therapy in the near future. (Source: Current Pharmacogenomics and Personalized Medicine)
Source: Current Pharmacogenomics and Personalized Medicine - April 25, 2017 Category: Genetics & Stem Cells Source Type: research

Impact of New Technologies on Pharmacogenomic s
Conclusion: The great development of new technologies can open promising insight on pharmacogenomics, allowing to study genes involved in pharmacokinetics and pharmacodynamics and providing holistic information of drug toxicity and efficacy. The understanding of therapeutic effects, adverse events and drugs interaction is still limited by incomplete knowledge of cellular pathways, therefore inferring interacting biological molecules involved in drug response is required. (Source: Current Pharmacogenomics and Personalized Medicine)
Source: Current Pharmacogenomics and Personalized Medicine - April 25, 2017 Category: Genetics & Stem Cells Source Type: research

DNA-drug Conjugates for Site-specific Delivery in Anti-cancer Therapy
Conclusion: The adduct would gradually release the drug at a physiological temperature and is thus well suited for site-specific targeted drug delivery with reduced side effects. (Source: Current Pharmacogenomics and Personalized Medicine)
Source: Current Pharmacogenomics and Personalized Medicine - April 25, 2017 Category: Genetics & Stem Cells Source Type: research

Editorial: CPPM Onward and Upward: Global Personalized Medicine Guided by Responsible Innovation
(Source: Current Pharmacogenomics and Personalized Medicine)
Source: Current Pharmacogenomics and Personalized Medicine - April 25, 2017 Category: Genetics & Stem Cells Source Type: research

Meet Our Editorial Board Member
(Source: Current Pharmacogenomics and Personalized Medicine)
Source: Current Pharmacogenomics and Personalized Medicine - April 25, 2017 Category: Genetics & Stem Cells Source Type: research

Retrometabolic Approach for Designing Personalized Anti- Cancer Drug Molecules for Controlling Breast Cancer Resulted by BRCA1 Mutations
Conclusion: The people with the genetic signatures, rs28897696 are more prone to breast cancer resulted by the BRCA1 mutation. For the PARP inhibition analysis, Human ARTD1 (PARP1) catalytic domain in complex with inhibitor Rucaparib (4RV6) has been considered. The inhibitors of PARP1 and BRCA1 have been designed in the retrometabolic manner from metabolites of chlorambucil and active/ inactive metabolites present in human body. The evolved molecules, 8-(5-acetyl-2-hydroxyphenoxy)-4-amino-3-hydroxy-5-methyloctanoic acid, 4-amino-3-hydroxy-9-(4-hydroxy-3-methoxyphenyl)-5,5-dimethyl-9-oxononanoic acid and 8-(5-acetyl-2-hydro...
Source: Current Pharmacogenomics and Personalized Medicine - January 16, 2017 Category: Genetics & Stem Cells Source Type: research